Back to results
US 12,590,126 B2Granted
Compounds for selective disruption of protein-protein interactions
AssigneeSyntheX, Inc.
InventorsCharly Chahwan, Maria Soloveychik
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair and cell death.
Claims4
A non-naturally occurring peptide comprising a targeting motif of Formula I or an invert thereof:
- (Formula I)
- (SEQ ID NO:
- 61)
- L-X1-R-X2-V-R-L-R-X3-Y1-L-R-X4
- wherein:
- X1-X4 and Y1 are independently selected from the 20 natural L- or D-amino acids,
- or Met(O), Met(O)2, Se-Met, Abu (α-aminobutyric acid), Bal (Beta-Alanine), Hse, nme-Ser, and Ahx;
- and wherein L, R, and V are D- or L-amino acids, wherein the peptide further comprises a cell-penetrating peptide motif, or a retro-invert thereof.
5 more elements
Dependencies are inferred from the claim text.